Constructing a Novel Amino Acid Metabolism Signature: A New Perspective on Pheochromocytoma Diagnosis, Immune Landscape, and Immunotherapy

Zechen Yan,Yongkun Luan,Yu Wang,Yilin Ren,Zhiyuan Li,Luyang Zhao,Linnuo Shen,Xiaojie Yang,Tonghu Liu,Yukui Gao,Weibo Sun
DOI: https://doi.org/10.1007/s10528-024-10733-5
2024-03-27
Biochemical Genetics
Abstract:Pheochromocytoma/paraganglioma (PGPG) is a rare neuroendocrine tumor. Amino acid metabolism is crucial for energy production, redox balance, and metabolic pathways in tumor cell proliferation. This study aimed to build a risk model using amino acid metabolism-related genes, enhancing PGPG diagnosis and treatment decisions. We analyzed RNA-sequencing data from the PCPG cohort in the GEO dataset as our training set and validated our findings using the TCGA dataset and an additional clinical cohort. WGCNA and LASSO were utilized to identify hub genes and develop risk prediction models. The single-sample gene set enrichment analysis, MCPCOUNTER, and ESTIMATE algorithm calculated the relationship between amino acid metabolism and immune cell infiltration in PCPG. The TIDE algorithm predicted the immunotherapy efficacy for PCPG patients. The analysis identified 292 genes with differential expression, which are involved in amino acid metabolism and immune pathways. Six genes (DDC, SYT11, GCLM, PSMB7, TYRO3, AGMAT) were identified as crucial for the risk prediction model. Patients with a high-risk profile demonstrated reduced immune infiltration but potentially higher benefits from immunotherapy. Notably, DDC and SYT11 showed strong diagnostic and prognostic potential. Validation through quantitative Real-Time Polymerase Chain Reaction and immunohistochemistry confirmed their differential expression, underscoring their significance in PCPG diagnosis and in predicting immunotherapy response. This study's integration of amino acid metabolism-related genes into a risk prediction model offers critical clinical insights for PCPG risk stratification, potential immunotherapy responses, drug development, and treatment planning, marking a significant step forward in the management of this complex condition.
genetics & heredity,biochemistry & molecular biology
What problem does this paper attempt to address?
The paper aims to address the following issues: 1. **Diagnosis and Treatment Decision**: By constructing a risk model based on amino acid metabolism-related genes to enhance the diagnosis and treatment decision-making for pheochromocytoma/paraganglioma (PCPG). 2. **Risk Stratification**: Identifying new sensitive diagnostic biomarkers for risk stratification of PCPG. 3. **Immunotherapy Response Prediction**: Developing a risk prediction model capable of predicting the response of pheochromocytoma patients to immunotherapy. 4. **Drug Development and Treatment Planning**: Providing key clinical insights for drug development and treatment planning for PCPG. Specifically, the study analyzed RNA sequencing data from the GEO dataset and validated it using the TCGA dataset and additional clinical cohorts. Through Weighted Gene Co-expression Network Analysis (WGCNA) and LASSO regression, six key genes (DDC, SYT11, GCLM, PSMB7, TYRO3, AGMAT) were identified, which play important roles in the risk prediction model. Additionally, the study showed that patients in the high-risk group had lower levels of immune infiltration but might benefit more from immunotherapy. Particularly, DDC and SYT11 have strong diagnostic and prognostic potential. The differential expression of these genes was confirmed by quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry, highlighting their importance in PCPG diagnosis and predicting immunotherapy response.